Engrail Therapeutics, Inc.

Founded in 2019 by Stephen Cunningham and Vikram Sudarsan, and based in California, US, Engrail Therapeutics, Inc. is a pharmaceutical company that focuses on the research and development of medicines to treat patients suffering from neurological disorders and diseases. In March 2024, Engrail Therapeutics, Inc. raised USD 157 million in Series B funding co-led by F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from Pivotal Life Sciences.

The firm’s partners include Pivotal Life Sciences, Forbion, Rivervest, Norwest, etc. The firm develops precision-targeted therapies for neuropsychiatric and neurologic disorders. The company's approach leverages advanced chemistry and pharmacology to create treatments that maximize efficacy while minimizing side effects. Their lead compound, ENX-102, targets GABAA receptors for generalized anxiety disorder, enhancing neurotransmission.

Additionally, the firm offers ENX-104 and ENX-105, compounds targeting dopamine D2/D3 receptors to address depression symptoms, including anhedonia. Moreover, the firm also develops ENX-103, a small molecule designed to correct copper transport defects in Menkes disease, facilitating proper copper distribution in the body. The company intends to use the March 2024 funding to support the development of its transformational therapies for neuropsychiatric and neurodevelopmental disorders.